IMMUNEONCO-B (01541) subsidiary Yiming Kaier Biopharmaceutical Technology (Shanghai) completes capital increase.

IMMUNEONCO-B (01541) announced that its subsidiary Yiming Kaier Biopharmaceutical Technology (Shanghai) has received a capital increase of RMB 50 million. As of the date of this announcement, the capital increase and the relevant industrial and commercial registration procedures relating to the capital increase have been completed. The investor has completed payment of the consideration of RMB 50 million in accordance with the capital increase agreement. Following the completion of the capital increase, the target company, Yiming Kaier Biopharmaceutical Technology (Shanghai) Co., Ltd., is held approximately 68.34%, 15.83%, 6.33%, 6.33% and 3.17% by the Company, Jiaxing Changxin, Shengke Qihang, Xinjie Chuangyuan and Mr. Wang, respectively. Accordingly, the target company remains a non-wholly-owned subsidiary of the Company, and its financial results continue to be consolidated into the Group's financial statements. The target company is principally engaged in the development of innovative drugs for metabolic diseases and rare diseases.